Key Takeaways The Food and Drug Administration (FDA) has intensified its scrutiny of the telehealth weight-loss market, publishing warning letters on June 16, 2026 to 25 companies for their marketing of compounded GLP-1-style medications and related products. The latest enforcement action expands on concerns previously raised by federal regulators and follows earlier FDA warnings directed […]
Key Takeaways The Food and Drug Administration (FDA) has intensified its scrutiny of the telehealth weight-loss market, publishing warning letters on June 16, 2026 to 25 companies for their marketing of compounded GLP-1-style medications and related products. The latest enforcement action expands on concerns previously raised by federal regulators and follows earlier FDA warnings directed […]
